^
Association details:
Biomarker:FGFR1 amplification
Cancer:Breast Cancer
Drug:zotatifin (eFT226) (eIF4A1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

B133 - eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers

Published date:
10/28/2019
Excerpt:
Solid tumor xenograft models harboring FGFR1/2 or HER2 amplifications treated with eFT226 resulted in significant in vivo tumor growth inhibition and regression at well tolerated doses in breast, non-small cell lung and colorectal cancer models.